# Activity, tolerability and resistance profile of the menin inhibitor ziftomenib in adults with relapsed or refractory NPM1-mutated AML

**Amir T. Fathi**<sup>1</sup>, Eunice S. Wang<sup>2</sup>, Ghayas C. Issa<sup>3</sup>, Jessica K. Altman<sup>4</sup>, Pau Montesinos<sup>5</sup>, Stephane DeBotton<sup>6</sup>, Roland Walter<sup>7</sup>, Kristen Pettit<sup>8</sup>, Stephen Strickland<sup>9</sup>, Mrinal Patnaik<sup>10</sup>, Marina Kremyanskaya<sup>11</sup>, Maria R. Baer<sup>12</sup>, James Foran<sup>13</sup>, Gary Schiller<sup>14</sup>, Lionel Ades<sup>15</sup>, Mael Heiblig<sup>16</sup>, Celine Berthon<sup>17</sup>, Jolanta Grembecka<sup>8</sup>, Tomasz Cierpicki<sup>8</sup>, Bradley Clegg<sup>8</sup>, Pierre Peterlin<sup>18</sup>, Eduardo Rodriguez Arboli<sup>19</sup>, Olga Salamero Garcia<sup>20</sup>, Cristina Papayannidis<sup>21</sup>, Kun Nie<sup>22</sup>, Julie Mackey<sup>22</sup>, Marilyn Tabachri<sup>22</sup>, Daniel Corum<sup>22</sup>, Mollie Leoni<sup>22</sup>, Stephen Dale<sup>22</sup>, Harry P. Erba<sup>23</sup>


<sup>&</sup>lt;sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY; <sup>3</sup>MD Anderson Cancer Center, Houston, TX; <sup>4</sup>Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago IL; <sup>5</sup>Hospital Universitari i Politècnic La Fe, Valencia, Spain; <sup>6</sup>Institut Gustave Roussy Service d'Hématologie Clinique, Paris, France; <sup>7</sup>Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>8</sup>University of Michigan, Ann Arbor, MI; <sup>9</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>10</sup>Mayo Clinic-Minnesota, Rochester, MN; <sup>11</sup>Mount Sinai-PRIME, New York, NY; <sup>12</sup>University of Maryland-Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; <sup>13</sup>Mayo Clinic-Florida, Jacksonville, FL; <sup>14</sup>UCLA Medical Center, Los Angeles, CA; <sup>15</sup>Hospital Saint-Louis, Paris, France; <sup>16</sup>Centre Hospitalier Lyon Sud, Lyon, France; <sup>17</sup>Centre Hospitalo-Universitarie Lille, Lille, France; <sup>18</sup>CHU de Nantes-Hôtel-Dieu, Nantes, France; <sup>19</sup>Hospitales Universitarios Virgen del Rocío, Sevilla, Spain; <sup>20</sup>Hospital Universitaria Vall d'Hebron-Institut de Recerca (VHIR), Barcelona, Spain; <sup>21</sup>IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; <sup>22</sup>Kura Oncology, Inc., San Diego, CA; <sup>23</sup>Duke Cancer Institute, Durham, NC

### **Disclosures**

### Amir T. Fathi, MD

• Consulting: Agios, Celgene/BMS, Astellas, Daiichi Sankyo, Takeda, Kura, Amgen, Pfizer, Seattle Genetics, AbbVie, and Genentech; Research support: Celgene/BMS and Agios


### NPM1-Mutant AML is a Large Genetic Subset<sup>1</sup> with a High Unmet Need



### No FDA-approved NPM1-m specific targeted therapies exist today in AML

# Ziftomenib Targets the Menin-KMT2A Pathway, a Foundational Target in AML


- NPM1-m and KMT2A-r drive overexpression of HOXA9/MEIS1 genes, critical for transformation to AML
- KMT2A(MLL) sits upstream from major AML targets (i.e., FLT3, IDH1/2, DNMT3A)
- KMT2A(MLL)-dependent genes contribute to therapeutic resistance and relapse to current therapies
- Menin inhibition downregulates HOXA9/MEIS1, leading to differentiation of leukemic blasts



KMT2A = lysine[K]-specific methyltransferase 2; MEIS1 = meis homeobox 1; MLL-mixed lineage leukemia; NPM1-c = cytoplasmic localization of nucleophosmin-1

1. Lu et al. Cancer Cell 2016;30(1):92–107; 2. Ferreira et al. Oncogene 2016;35(23):3079-82; 3. Jeong et al. Nat. Genet 2014;46(1):17-23; 4. Wang et al. Blood 2005;106(1):254–64; 5. Chowdhury et al. EMBO Rep 2011;12(5):463-9; 6. Schmidt et al. Leukemia 2019;33(7):1608-19; 7. Xu et al. Cancer Cell 2016;30(6):863-78; 8. Collins & Hess. Curr Opin Hematol 2016;23(4):354-61; 9. Brunetti et al. Cancer Cell 2018; 34(3):499–512.

# KOMET-001 Phase 1/2 Study of Ziftomenib in R/R AML



### **Baseline Patient Characteristics**

Demographics	600 mg, n = 20	Disposition	600 mg, n = 20	
Age, median (min, max), y	70.5 (22, 86)	Patients in follow-up, n (%)	7 (35)	
Male, n (%)	6 (30)	Reason for treatment discontinuation, n ( $\%$ )		
ECOG PS 0, n (%)	3 (15)			
PS 1	14 (70)	Adverse event (not study drug-related) <sup>2</sup>	5 (25)	
PS 2	3 (15)	Death	1 (5)	
Number of prior therapies, median (min, max)	3 (1,10)	Disease progression (including clinical)	9 (45)	
Prior venetoclax, n (%)	13 (65)	All other reasons <sup>3</sup>	5 (25)	
Prior SCT, n (%)	4 (20)	Patients off study, n (%)	13 (65)	
Co-mutations, n (%)		Descenter dudy discertinuation of (97)		
FLT3 <sup>1</sup>	6 (30)	Reason for study discontinuation, n (%)		
IDH1/2 <sup>1</sup>	8 (40)	Death	13 (65)	
Co-mutations with both FLT3 and IDH1/2	4 (20)			

<sup>1</sup>Patient could have both FLT3 and IDH1/2 and be counted in both co-mutation categories.
 <sup>2</sup>These adverse events leading to discontinuation were not considered study drug related.
 <sup>3</sup>Additional reasons for treatment discontinuation include physician decision, receipt of alternative anticancer treatment, withdrawal by subject, and other.


### Phase 1b Safety and Tolerability of Ziftomenib in R/R NPM1-m AML

≥ 20% Treatment-Emergent Adverse Events, n (%)	NPM1-m, n = 20		
Patients with TEAEs (All Grades)	19 (95)		
Diarrhea	9 (45)		
Hypokalemia	8 (40)		
Nausea	6 (30)		
Anemia	6 (30)		
Back pain	6 (30)		
Epistaxis	5 (25)		
Patients with TEAEs (≥ Grade 3)	17 (85)		
Anemia	5 (25)		
Thrombocytopenia	4 (20)		

$\geq$ 20% Treatment-Related Adverse Events, n (%)	NPM1-m, n = 20		
Patients with TRAEs (All Grades)	12 (60)		
Nausea	4 (20)		
Differentiation Syndrome	4 (20)		
Patients with TRAEs (≥Grade 3)	6 (30)		
N/A			

- No reports of drug-induced QTc prolongation
- 1 report of grade 3 differentiation syndrome
  - manageable with mitigation strategy
- Other reports of DS Grade  $\leq 2$

# Ziftomenib Demonstrates Encouraging Clinical Activity



- Co-mutations in FLT3 and IDH1/2 did not affect chances of response to single agent ziftomenib
- 1 patient achieved CRi, proceeded to HSCT, and achieved and remains in CR
- Median time to first response: 51 days


HSCT, hematopoietic stem cell transplantation; MLFS, morphological leukemia-free state

#### 12-April-2023 Data Cut

### Ziftomenib Monotherapy Drives Durable Responses

- Median DoR 8.2 months

   (95% CI: 1.0 to Not Evaluable)
   with a median follow up time
   of 8.8 months
- Patient 1 remained on ziftomenib in CR (MRD-) into Cycle 36
- Patients 9 and 21 proceeded to HSCT
  - Patient 9 remains in complete response on ziftomenib for post-HSCT maintenance
  - Patient 21 remains in complete response



### Ziftomenib Clears Measurable Residual Disease (MRD), Including Sub-Clones

### Local MRD Analysis<sup>1</sup>

• 67% of patients (4 of 6) achieving CRc were MRD-negative<sup>2</sup>

### Ongoing Central MRD Analysis, by NGS (Representative Patients)<sup>3</sup>

Subject 1: Prior Tx with midostaurin	NPM1	FLT3-TKD	IDH1	Subject 2: Prior Tx with	NPM1	FLT3-ITD	IDH2
	Variant Allele Frequency (%)			midostaurin and gilteritinib	Variant Allele Frequency (%)		
C1 D28	33	33	35	C1 D28	47	91	46
C5 D28	Not detected	Not detected	Not detected	C4 D28	0.37	0.87	0.41

<sup>1</sup>4 patients by multiparameter flow cytometry (MFC), 1 patient by NGS, 1 patient RT-qPCR.


<sup>2</sup>6 of 8 patients who achieved CRc were tested for MRD status (local MRD test).

<sup>3</sup>Mutations detected in MyMRD NGS (Invivoscribe, San Diego, CA).

CRc is defined as achieving best overall response of any of the following: CR, CRh, CRi (including CRp). MRD, measurable residual disease. NGS, Next Generation Sequencing.

# Ziftomenib Active Against Known Menin Gatekeeper Mutations

- No major conformational changes observed in Menin<sup>T349M</sup> vs. wild-type (WT) protein
- M327 and Y324 side chains adopt new conformations in Menin<sup>T349M</sup> but do not affect ziftomenib binding
- Binding affinity of ziftomenib is reduced for Menin<sup>M3271</sup> but unaffected for Menin<sup>T349M</sup>
  - Per Armstrong lab<sup>1</sup>, ziftomenib also retains activity against Menin<sup>G331R</sup>
- Ziftomenib retains activity against 2 of 3 known MEN1 mutant loci



### Ziftomenib Appears Less Susceptible to Observed Mutations Associated with Resistance to Menin Inhibition

• Following reports of *MEN1* resistance mutations with another menin inhibitor<sup>1</sup>, an analysis of KOMET-001 identified 1 of 29 subjects (3.4%) with the resistance mutation (MEN1-M327I) acquired while on ziftomenib<sup>2</sup>



- MEN1 mutant RNA was not detected in 13 of 13 other subjects who received ≥ 2 cycles of ziftomenib and had best response of SD or PD, suggesting that progression or lack of response in these subjects is not due to MEN1 mutations
- Ziftomenib's ability to target MEN1 harboring G331R or T349M mutations may in part explain the low frequency of MEN1 resistance mutations detected in KOMET-001 subjects
- Further analysis is underway to continue to characterize mechanisms of menin resistance

### Conclusions

- Ziftomenib demonstrates significant clinical activity with 45% ORR (35% CR rate) and lack of myelosuppression, with maintained count recovery in heavily pretreated R/R NPM1-m AML
- Durable remissions with MRD clearance of foundational NPM1-m and other key co-mutations, including FLT3 ITD/TKD and IDH1/2, observed with ziftomenib monotherapy
- Resistance mutations have developed infrequently and ziftomenib retains activity against common menin gatekeeper mutations
- Ziftomenib is well tolerated, with no drug induced QTc and manageable DS; the lack of predicted adverse drug-drug interactions is supportive of combination approaches
- The pivotal KOMET-001 trial is currently recruiting patients with R/R NPM1-m AML
- KOMET-007 Phase 1 is open for enrollment (NCT05735184), studying ziftomenib in combination with existing intensive chemotherapy (IC) and non-intensive chemotherapy (NIC) standards of care (SOC) in newly diagnosed and R/R NPM1-m or KMT2A-r AML

# **Acknowledgements**

- The patients, their families, and caregivers
- The study investigators and their study teams:
  - Centre Hospitalier Lyon-Sud
  - CHU de Lille
  - CHU de Nantes Hôtel Dieu
  - Duke Cancer Institute
  - Fred Hutchinson Cancer Center
  - Gustave Roussy
  - Hôpital Saint Louis
  - Hospital Clínic de Barcelona
  - Hospital Universitari i Politècnic La Fe
  - Hospital Universitario Central de Asturias
  - Hospital Universitari Vall d'Hebron

- Hospital Universitario Virgen del Rocío
- Indiana University
- IRCCS Azienda Ospedaliero
   Universitaria di Bologna
- Massachusetts General Hospital
- Mayo Clinic-Florida
- Mayo Clinic-Rochester
- MD Anderson Cancer Center
- MD Anderson Cancer Center Madrid
- Mount Sinai

- Northwestern University
- Roswell Park
- UCLA
- University of Maryland
- University of Michigan
- UPMC-Pittsburgh
- Vanderbilt University

• The study is sponsored by Kura Oncology, Inc.